vs
碧迪（BDX）与Vistra Corp.（VST）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Vistra Corp.的1.1倍（$5.3B vs $4.8B），碧迪净利率更高（7.3% vs 4.8%，领先2.4%），Vistra Corp.同比增速更快（31.2% vs -0.4%），Vistra Corp.自由现金流更多（$596.0M vs $549.0M），过去两年Vistra Corp.的营收复合增速更高（23.3% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
股票代码为VST的Vistra Corp是总部位于美国得克萨斯州的能源企业，主营电力生产、可再生能源开发及能源零售等业务。此外“Vistra”也可指一家总部位于中国香港的企业服务提供商，为全球客户提供公司注册、合规管理等专业服务。
BDX vs VST — 直观对比
营收规模更大
BDX
是对方的1.1倍
$4.8B
营收增速更快
VST
高出31.6%
-0.4%
净利率更高
BDX
高出2.4%
4.8%
自由现金流更多
VST
多$47.0M
$549.0M
两年增速更快
VST
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $4.8B |
| 净利润 | $382.0M | $233.0M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 9.9% |
| 净利率 | 7.3% | 4.8% |
| 营收同比 | -0.4% | 31.2% |
| 净利润同比 | 24.0% | -47.2% |
| 每股收益（稀释后） | $1.34 | $0.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXVST
| Q4 25 | $5.3B | $4.8B | ||
| Q3 25 | $5.9B | $4.8B | ||
| Q2 25 | $5.5B | $3.8B | ||
| Q1 25 | $5.3B | $4.3B | ||
| Q4 24 | $5.2B | $3.7B | ||
| Q3 24 | $5.4B | $4.3B | ||
| Q2 24 | $5.0B | $3.6B | ||
| Q1 24 | $5.0B | $3.2B |
净利润BDXVST
| Q4 25 | $382.0M | $233.0M | ||
| Q3 25 | $493.0M | $652.0M | ||
| Q2 25 | $574.0M | $327.0M | ||
| Q1 25 | $308.0M | $-268.0M | ||
| Q4 24 | $303.0M | $441.0M | ||
| Q3 24 | $400.0M | $1.9B | ||
| Q2 24 | $487.0M | $365.0M | ||
| Q1 24 | $537.0M | $-35.0M |
毛利率BDXVST
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXVST
| Q4 25 | 10.5% | 9.9% | ||
| Q3 25 | 11.8% | 21.7% | ||
| Q2 25 | 16.0% | 13.7% | ||
| Q1 25 | 10.4% | -2.8% | ||
| Q4 24 | 8.8% | 16.4% | ||
| Q3 24 | 11.4% | 59.6% | ||
| Q2 24 | 12.1% | 22.5% | ||
| Q1 24 | 14.5% | 2.7% |
净利率BDXVST
| Q4 25 | 7.3% | 4.8% | ||
| Q3 25 | 8.4% | 13.6% | ||
| Q2 25 | 10.4% | 8.7% | ||
| Q1 25 | 5.8% | -6.3% | ||
| Q4 24 | 5.9% | 12.0% | ||
| Q3 24 | 7.4% | 43.5% | ||
| Q2 24 | 9.8% | 10.1% | ||
| Q1 24 | 10.6% | -1.1% |
每股收益（稀释后）BDXVST
| Q4 25 | $1.34 | $0.55 | ||
| Q3 25 | $1.71 | $1.75 | ||
| Q2 25 | $2.00 | $0.81 | ||
| Q1 25 | $1.07 | $-0.93 | ||
| Q4 24 | $1.04 | $1.09 | ||
| Q3 24 | $1.37 | $5.25 | ||
| Q2 24 | $1.68 | $0.90 | ||
| Q1 24 | $1.85 | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $785.0M |
| 总债务越低越好 | — | $15.8B |
| 股东权益账面价值 | $25.3B | $5.1B |
| 总资产 | $54.8B | $41.5B |
| 负债/权益比越低杠杆越低 | — | 3.11× |
8季度趋势，按日历期对齐
现金及短期投资BDXVST
| Q4 25 | $740.0M | $785.0M | ||
| Q3 25 | $641.0M | $602.0M | ||
| Q2 25 | $735.0M | $458.0M | ||
| Q1 25 | $667.0M | $561.0M | ||
| Q4 24 | $711.0M | $1.2B | ||
| Q3 24 | $1.7B | $905.0M | ||
| Q2 24 | $4.5B | $1.6B | ||
| Q1 24 | $2.3B | $1.1B |
总债务BDXVST
| Q4 25 | — | $15.8B | ||
| Q3 25 | — | $15.8B | ||
| Q2 25 | — | $15.5B | ||
| Q1 25 | — | $15.4B | ||
| Q4 24 | — | $15.4B | ||
| Q3 24 | — | $13.9B | ||
| Q2 24 | — | $13.9B | ||
| Q1 24 | — | $14.7B |
股东权益BDXVST
| Q4 25 | $25.3B | $5.1B | ||
| Q3 25 | $25.4B | $5.2B | ||
| Q2 25 | $25.5B | $4.8B | ||
| Q1 25 | $25.2B | $4.8B | ||
| Q4 24 | $25.2B | $5.6B | ||
| Q3 24 | $25.9B | $5.4B | ||
| Q2 24 | $25.9B | $5.6B | ||
| Q1 24 | $25.6B | $5.7B |
总资产BDXVST
| Q4 25 | $54.8B | $41.5B | ||
| Q3 25 | $55.3B | $38.0B | ||
| Q2 25 | $54.9B | $38.1B | ||
| Q1 25 | $54.5B | $38.2B | ||
| Q4 24 | $54.7B | $37.8B | ||
| Q3 24 | $57.3B | $37.9B | ||
| Q2 24 | $55.6B | $39.1B | ||
| Q1 24 | $54.2B | $38.2B |
负债/权益比BDXVST
| Q4 25 | — | 3.11× | ||
| Q3 25 | — | 3.02× | ||
| Q2 25 | — | 3.22× | ||
| Q1 25 | — | 3.20× | ||
| Q4 24 | — | 2.77× | ||
| Q3 24 | — | 2.56× | ||
| Q2 24 | — | 2.49× | ||
| Q1 24 | — | 2.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $1.4B |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $596.0M |
| 自由现金流率自由现金流/营收 | 10.5% | 12.4% |
| 资本支出强度资本支出/营收 | 2.1% | 17.4% |
| 现金转化率经营现金流/净利润 | 1.72× | 6.15× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $1.3B |
8季度趋势，按日历期对齐
经营现金流BDXVST
| Q4 25 | $657.0M | $1.4B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.2B | $572.0M | ||
| Q1 25 | $164.0M | $599.0M | ||
| Q4 24 | $693.0M | $1.4B | ||
| Q3 24 | $1.2B | $1.7B | ||
| Q2 24 | $1.3B | $1.2B | ||
| Q1 24 | $514.0M | $312.0M |
自由现金流BDXVST
| Q4 25 | $549.0M | $596.0M | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.0B | $-118.0M | ||
| Q1 25 | $35.0M | $-169.0M | ||
| Q4 24 | $588.0M | $923.0M | ||
| Q3 24 | $882.0M | $1.0B | ||
| Q2 24 | $1.1B | $698.0M | ||
| Q1 24 | $380.0M | $-153.0M |
自由现金流率BDXVST
| Q4 25 | 10.5% | 12.4% | ||
| Q3 25 | 17.0% | 21.1% | ||
| Q2 25 | 19.0% | -3.1% | ||
| Q1 25 | 0.7% | -4.0% | ||
| Q4 24 | 11.4% | 25.2% | ||
| Q3 24 | 16.2% | 23.4% | ||
| Q2 24 | 22.4% | 19.4% | ||
| Q1 24 | 7.5% | -4.8% |
资本支出强度BDXVST
| Q4 25 | 2.1% | 17.4% | ||
| Q3 25 | 6.0% | 9.6% | ||
| Q2 25 | 3.2% | 18.4% | ||
| Q1 25 | 2.4% | 18.1% | ||
| Q4 24 | 2.0% | 11.7% | ||
| Q3 24 | 5.4% | 15.8% | ||
| Q2 24 | 3.6% | 13.8% | ||
| Q1 24 | 2.7% | 14.7% |
现金转化率BDXVST
| Q4 25 | 1.72× | 6.15× | ||
| Q3 25 | 2.75× | 2.25× | ||
| Q2 25 | 2.12× | 1.75× | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 2.29× | 3.07× | ||
| Q3 24 | 2.94× | 0.90× | ||
| Q2 24 | 2.66× | 3.28× | ||
| Q1 24 | 0.96× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
VST
| Retail Energy Charge In ERCOT | $2.1B | 43% |
| Retail Energy Charge In Northeast Midwest | $1.2B | 24% |
| East Segment | $1.1B | 24% |
| Hedging Revenue Realized | $170.0M | 4% |
| Revenue From Other Wholesale Contracts | $116.0M | 2% |
| Transferable Production Tax Credit Revenues | $78.0M | 2% |
| West Segment | $77.0M | 2% |
| Intersegment Sales | $25.0M | 1% |
